Raised Serum Tumour Markers Predict Incomplete Cytoreduction, Disease-Free and Overall Survival in Patients with Colorectal Peritoneal Metastases Treated by Cytoreductive Surgery and HIPEC | Synapse
March 3, 2026
Raised Serum Tumour Markers Predict Incomplete Cytoreduction, Disease-Free and Overall Survival in Patients with Colorectal Peritoneal Metastases Treated by Cytoreductive Surgery and HIPEC
Key Points
Raised serum tumour markers correlate with incomplete cytoreduction, leading to poorer outcomes.
Patients with elevated markers experience reduced disease-free and overall survival rates compared to others.
Assessment using serum tumour markers provides insight into surgical efficacy in managing metastatic disease.
Implications highlight the importance of regular monitoring of serum tumour markers for better treatment planning.